FOXP1: A potential therapeutic target in cancer

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 7, 2007, Pages 955-965

  Koon, Henry B ^a   Ippolito, Gregory C ^b   Banham, Alison H ^c   Tucker, Philip W ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

3p; Forkhead; Foxp1; Lymphoma; Oncogene; Transcription factor; Tumour suppressor

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; FORKHEAD TRANSCRIPTION FACTOR P1; RITUXIMAB; UNCLASSIFIED DRUG;

B CELL LYMPHOMA; B LYMPHOCYTE; BREAST CANCER; CELL MATURATION; CHROMOSOME 3P; CHROMOSOME TRANSLOCATION; DIGESTIVE SYSTEM CANCER; FOLLICULAR LYMPHOMA; GENE LOCUS; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HEART DEVELOPMENT; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LUNG CANCER; LUNG DEVELOPMENT; LYMPHOCYTE; LYMPHOMA; MONOTHERAPY; ONCOGENE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; TUMOR SUPPRESSOR GENE; UROGENITAL TRACT CANCER;

ANIMALS; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; NEOPLASMS; ONCOGENES; REPRESSOR PROTEINS;

EID: 34447295971     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.7.955     Document Type: Review

References (79)

1. HECHT JL, ASTER JC: Molecular biology of Burkitt's lymphoma. J. Clin. Oncol. (2000) 18(21):3707-3721.
2. SCHUSTER MB, PORSE BT: C/EBPα: a tumour suppressor in multiple tissues? Biochim. Biophys. Acta (2006) 1766(1):88-103.
3. BANHAM AH, BEASLEY N, CAMPO E et al.: The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res. (2001) 61(24):8820-8829.
4. BANHAM AH, CONNORS JM, BROWN PJ et al.: Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin. Cancer Res. (2005) 11(3):1065-1072.
5. BARRANS SL FENTON JA, BANHAM A, OWEN RG, JACK AS: Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood (2004) 104(9):2933-2935.
6. CARLSSON P,, MAHLAPUU M: Forkhead transcription factors: key players in development and metabolism. Dev. Biol. (2002) 250(1):1-23.
7. KATOH M, KATOH M: Human FOX gene family (Review). Int. J. Oncol. (2004) 25(5):1495-1500.
8. HU H, WANG B, BORDE M et al.: Foxp 1 is an essential transcriptional regulator of B cell development. Nat. Immunol. (2006)7(8):819-826.
9. SHU W, YANG H, ZHANG L, LU MM, MORRISEY EE: Characterization of a new subfamily of winged-helix/forkhead (Fox) genes that are expressed in the lung and act as transcriptional repressors. J. Biol. Chem. (2001) 276(29):27488-27497.
10. WANG B, WEIDENFELD J, LU MM et al.: Foxp 1 regulates cardiac outflow tract, endocardial cushion morphogenesis and myocyte proliferation and maturation. Development (2004) 131(18):4477-4487.
11. SHI C, ZHANG X, CHEN Z et al.: Integrin engagement regulates monocyte differentiation through the forkhead transcription factor Foxp 1. J. Clin. Invest. (2004) 114(3):408-418.
12. STREUBEL B, VINATZER U, LAMPRECHT A, RADERER M, CHOTT A: T(3; 14) (p 14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia (2005) 19(4):652-658.
13. WLODARSKA I, VEYT E, DE PAEPE P et al.: FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia (2005) 19(8):1299-1305.
14. FOX SB, BROW NP, HAN C et al.: Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor α and improved surviral in primary human breast carcinomas. Clin. Cancer Res. (2004) 10(10):3521-3527.
15. GIATROMANOLAKI A, KOUKOURAKIS MI, SIVRIDIS E et al.: Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1α expression. Mod. Pathol. (2006) 19(1):9-16.
16. LI C, TUCKER PW: DNA-binding properties and secondary structural model of the hepatocyte nuclear factor 3/fork head domain. Proc Natl. Acad. Sci. USA (1993) 90(24):11583-11587.
17. HUEBNER K: Tumor suppressors on 3p: a neoclassic quartet. Proc. Natl. Acad. Sci. USA (2001) 98(26):14763-14765.
18. ZABAROVSKY ER, LERMAN MI, MINNA JD: Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene (2002) 21(45):6915-6935.
19. HOEFNAGEL JJ, MULDER MM, DREEF E et al.: Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma. Mod. Pathol. (2006) 19 (9): 1270-1276.
20. CRESPI BJ: Sly FOXP2: genomic conflict in the evolution of language. Trends Ecol. Evol. (2007).
21. LAI CS, FISHERSE, HURST JA, VARGHA-KHADEM F, MONACO AP: A forkhead-domain gene is mutated in a severe speech and language disorder. Nature (2001) 413(6855):519-523.
22. CHATILA TA, BLAESER F, HO N et al.: JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J. Clin. Invest. (2000) 106(12):R75-R81.
23. BENNETT CL, OCHS HD: IPEX is a unique X-linked syndrome characterized by immune dysfunction, polyendocrinopathy, enteropathy, and a variety of autoimmune phenomena. Curr. Opin. Pediatr. (2001) 13(6):533-538.
24. ZIEGLER SF: FOXP3: of mice and men. Annu. Rev. Immunol. (2006) 24:209-226.
25. TEUFEL A, WONG EA, MUKHOPADHYAY M, MALIK N, WESTPHAL H: FoxP4, a novel forkhead transcription factor. Biochim. Biophys. Acta (2003) 1627(2-3):147-152.
26. LI S, ZHOU D, LU MM, MORRISEY EE: Advanced cardiac morphogenesis does not require heart tube fusion. Science (2004) 305(5690):1619-1622.
27. DE LA POMPA JL, TIMMERMAN LA, TAKIMOTO H et al.: Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum. Nature (1998) 392(6672): 182-186.
28. WANG B, LIN D, LI C, TUCKER P: Multiple domains define the expression and regulatory properties of Foxp1 forkhead transcriptional repressors. J. Biol. Chem. (2003) 278(27):24259-24268.
29. LI S, WEIDENFELD J, MORRISEY EE: Transcriptional and DNA binding activity of the Foxp 1/2/4 family is modulated by heterotypic and homotypic protein interactions. Mol. Cell Biol. (2004) 24(2):809-822.
30. COFFER PJ, BURGERING BM: Forkhead-box transcription factors and their role in the immune system. Nat. Rev. Immunol. (2004) 4(11):889-899.
31. SCHUBERT LA, JEFFERY E, ZHANG Y, RAMSDELL F, ZIEGLER SF: Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation. J. Biol. Chem. (2001) 276(40):37672-37679.
32. BETTELLI E, DASTRANGE M, OUKKA M: Foxp3 interacts with nuclear factor of activated T cells and NF-KB to repress cytokine gene expression and effector functions of T helper cells. Proc. Natl. Acad. Sci. USA (2005) 102(14):5138-5143.
33. FOX AH, LAM YW, LEUNG AK et al.: Paraspeckles: a novel nuclear domain. Curr. Biol. (2002) 12(1):13-25.
34. WU Y, BORDE M, HEISSMEYER V et al.: FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell (2006) 126(2):375-387.
35. RAO A, LUO C, HOGAN PG: Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol. (1997) 15:707-747.
36. CRABTREE GR, OLSON EN: NFAT signaling: choreographing the social lives of cells. Cell (2002) 109(Suppl.):S67-S79.
37. HANS CP, WEISENBURGER DD, GREINER TC et al.: Expression of PKC-β or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod. Pathol. (2005) 18(10):1377-1384.
38. BUSSLINGER M: Transcriptional control of early B cell development. Annu. Rev. Immunol. (2004) 22:55-79.
39. MURRE C: Helix-loop-helix proteins and lymphocyte development. Nat. Immunol. (2005) 6(11):1079-1086.
40. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. (2001) 182:18-32.
41. + suppressor T cells: more questions than answers. Nat. Rev. Immunol. (2002) 2(6):389-400.
42. + regulatory T cells. Nat. Immunol. (2003) 4(4):330-336.
43. HORI S, NOMURA T, SAKAGUCHI S: Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 299(5609):1057-1061.
44. + T regulatory cells. Nat. Immunol. (2003) 4(4):337-342.
45. + regulatory T cells: Current controversies and future perspectives. Eur. J. Immunol. (2006) 36(11):2832-2836.
46. MARSON A, KRETSCHMER K, FRAMPTON GM et al.: Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature (2007) 445(7130):931-935.
47. SHU W, LU MM, ZHANG Y et al.: Foxp2 and Foxp1 cooperatively regulate lung and esophagus development. Development (2007) 134(10):1991-2000.
48. DUMON KR, ISHII H, FONG LY et al.: FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc. Natl. Acad. Sci. USA (2001) 98(6):3346-3351.
49. XIAN J, AITCHISON A, BOBROW L et al.: Targeted disruption of the 3p 12 gene, Dutt1/Robo1, predisposes mice to lung adenocarcinomas and lymphomas with methylation of the gene promoter. Cancer Res. (2004) 64(18):6432-6437.
50. SHIMIZU K, KATO A, HINOTSUME D et al.: Reduced expressions of Foxp1 and Rassf1a genes in lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine in rats. Cancer Lett. (2006) 236(2):186-190.
51. BANHAM AH, BODDY J, LAUNCHBURY R et al.: Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by Androgens or hypoxia. Prostate (2007).
52. BROWN P, MARAFIOTI T, KUSEC R, BANHAM AH: The FOXP1 transcription factor is expressed in the majority of follicular lymphomas but is rarely expressed in classical and lymphocyte predominant Hodgkin's lymphoma. J. Mol. Histol. (2005) 36(4):249-256.
53. HARALAMBIEVA E, ADAM P, VENTURA R et al.: Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation. Leukemia (2006) 20(7):1300-1303.
54. BARRANS SL, FENTON JAL, VENTURA R et al.: Deregulated over expression of FOXP1 protein in diffuse large B-cell lymphoma does not occur as a result of gene rearrangement. Haematologica (2007) (In Press).
55. A predictive model for aggressive non-Hodgkin's lymphoma. The International non-Hodgkin's lymphoma prognostic factors project. N. Engl. J. Med. (1993) 329(14):987-994.
56. ALIZADEH AA, EISEN MB, DAVIS RE et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 403(6769):503-511.
57. ATKINS CD: A predictive model for non-Hodgkin's lymphoma. N. Engl. J. Med. (1994) 330(8):574-575.
58. ROSENWALD A, WRIGHT G, CHAN WC et al.: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. (2002) 346(25):1937-1947.
59. SHIPP MA, ROSS KN, TAMAYO P et al.: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. (2002) 8(1):68-74.
60. SAGAERT X, DE PAEPE P, LIBBRECHT L et al.: Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J. Clin. Oncol. (2006) 24(16):2490-2497.
61. SHAFFER AL, ROSENWALD A, STAUDT LM: Lymphoid malignancies: the dark side of B-cell differentiation. Nat. Rev. Immunol. (2002) 2(12):920-932.
62. BEA S, ZETTL A, WRIGHT G et al.: Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood (2005) 106(9):3183-3190.
63. HANS CP, WEISENBURGER DD, GREINER TC et al.: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood (2004) 103(1):275-282.
64. DE PAEPE P, DE WOLF-PEETERS C: Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia (2007) 21(1):37-43.
65. GILMORETD, KALAITZIDIS D, LIANG MC, STARCZYNOWSKI DT: The c-Rel transcription factor and B-cell proliferation: a deal with the devil. Oncogene (2004) 23(13):2275-2286.
66. MARAFIOTI T, POZZOBON M, HANSMANN ML et al.: The NFATc1 transcription factor is widely expressed in white cells and translocates from the cytoplasm to the nucleus in a subset of human lymphomas. Br. J. Haematol. (2005) 128(3):333-342.
67. FU L, LIN-LEE YC, PHAM LV et al.: Constitutive NF-κB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood (2006) 107(11):4540-4548.
68. PHAM LV, TAMAYO AT, YOSHIMURA LC, LIN-LEE YC, FORD RJ: Constitutive NF-κB and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD 154 gene and maintains lymphoma cell survival. Blood (2005) 106(12):3940-3947.
69. PAJER P, PECENKA V, KRALOVA J et al.: Identification of potential human oncogenes by mapping the common viral integration sites in avian nephroblastoma. Cancer Res. (2006) 66(1):78-86.
70. RUBENSTEIN JL, FRIDLYAND J, ABREY L et al.: Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J. Clin. Oncol. (2007).
71. FARINHA P, GASCOYNE RD: Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J. Clin. Oncol. (2005) 23(26):6370-6378.
72. REMSTEIN ED, DOGAN A, EINERSON RR et al.: The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. Am. J. Surg. Pathol. (2006) 30(12):1546-1553.
73. SENFF NJ, HOEFNAGEL JJ, JANSEN PM et al.: Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J. Clin. Oncol. (2007).
74. SAVAGE KJ, MONTI S, KUTOK JL et al.: The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood (2003) 102(12):3871-3879.
75. HACEIN-BEY-ABINA S, VON KALLE C, SCHMIDT M et al.: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-XI. Science (2003) 302(5644):415-419.
76. YANG L, BAILEY L, BALTIMORE D, WANG P: Targeting lentiviral vectors to specific cell types in vivo. Proc. Natl. Acad. Sci. USA (2006) 103(31): 11479-11484.
77. BROMBERG J, DARNELL JE JR: The role of STATs in transcriptional control and their impact on cellular function. Oncogene (2000) 19(21):2468-2473.
78. STITT TN, DRUJAN D, CLARKE BA et al.: The IGF-1/PJ3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell (2004) 14(3):395-403.
79. BEDIKIAN AY, MILLWARD M, PEHAMBERGER H et al.: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. Clin. Oncol. (2006) 24(29):4738-4745.